Our data on COVID-19 vaccinations is updated each morning (London time), with the most recent official numbers up to the previous day.
In our Data Explorer you can see our data on the cumulative number of COVID-19 vaccination doses administered. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses). You can find charts with the number of people with at least 1 dose, and the number of people fully vaccinated, further down this page.
→ Open the Data Explorer in a new tab.
Select a group of countries at once: all European countries, 30 largest countries; EU; Americas; OECD.
To bring this pandemic to an end, a large share of the world needs to be immune to the virus. The safest way to achieve this is with a vaccine. Vaccines are a technology that humanity has often relied on in the past to bring down the death toll of infectious diseases.
Within less than 12 months after the beginning of the COVID-19 pandemic, several research teams rose to the challenge and developed vaccines that protect from SARS-CoV-2, the virus that causes COVID-19.
Now the challenge is to make these vaccines available to people around the world. It will be key that people in all countries — not just in rich countries — receive the required protection. To track this effort we at Our World in Data are building the international COVID-19 vaccination dataset that we make available on this page. It is updated each morning, with the most recent official numbers up to the previous day.
- Data sources: at the end of this page you find a detailed list of all our country-specific sources.
- Open access: as with all of our data, we are making this dataset openly available, so that everyone can check and use the data that we bring together. You find the vaccination data in our daily-updated repository on GitHub.
Country-by-country data on COVID-19 vaccinations
This page has a number of charts on vaccination. In the box below you can select any country you are interested in — or several, if you want to compare countries.
All charts on this page will then show data for the countries that you selected.
The following chart shows the daily number of COVID-19 vaccination doses administered per 100 people. This is shown as the rolling seven-day average. Note that this is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses).
The following map and chart show the number of COVID-19 vaccination doses administered per 100 people within a given population. Note that this is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime as several available COVID vaccines require multiple doses.
The following chart shows the total number of COVID-19 vaccination doses administered. Note that this is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses).
The following chart shows the share of the total population that has received at least one dose of the COVID-19 vaccine. This may not equal the share that are fully vaccinated if the vaccine requires two doses. If a person receives the first dose of a 2-dose vaccine, this metric goes up by 1. If they receive the second dose, the metric stays the same.
The following chart shows the total number of people that have received at least one dose of the COVID-19 vaccine. This may not equal the number that are fully vaccinated if the vaccine requires two doses. If a person receives the first dose of a 2-dose vaccine, this metric goes up by 1. If they receive the second dose, the metric stays the same.
The following chart shows the share of the total population that has been fully vaccinated against COVID-19. This represents the share that have received all doses prescribed by the vaccination protocol. If a person receives the first dose of a 2-dose vaccine, this metric stays the same. If they receive the second dose, the metric goes up by 1.
This data is only available for countries which report the breakdown of doses administered by first and second doses.
The following chart shows the total number of people that have been fully vaccinated against COVID-19. This represents the number that have received all doses prescribed by the vaccination protocol. If a person receives the first dose of a 2-dose vaccine, this metric stays the same. If they receive the second dose, the metric goes up by 1.
This data is only available for countries which report the breakdown of doses administered by first and second doses.
The following chart shows the cumulative number of doses administered, broken down by vaccine manufacturer.
This is only available for a select number of countries which report the necessary data.
This interactive chart maps government policies on COVID-19 vaccination. Note that this only tracks policies on the availability of vaccinations. It does not track the number of people who have been vaccinated.
Countries are grouped into six categories:
- No availability
- Availability for ONE of following: key workers/ clinically vulnerable groups / elderly groups
- Availability for TWO of following: key workers/ clinically vulnerable groups / elderly groups
- Availability for ALL of following: key workers/ clinically vulnerable groups / elderly groups
- Availability for all three plus partial additional availability (select broad groups/ages)
- Universal availability
Vaccination policy data is sourced from the Oxford Coronavirus Government Response Tracker
This data on vaccination policies is sourced from the Oxford Coronavirus Government Response Tracker (OxCGRT).
This resource is published by researchers at the Blavatnik School of Government at the University of Oxford: Thomas Hale, Anna Petherik, Beatriz Kira, Noam Angrist, Toby Phillips and Samuel Webster.
The tracker presents data collected from public sources by a team of over one hundred Oxford University students and staff from every part of the world.
The data presented here is taken directly from the OxCGRT project; Our World in Data do not track policy responses ourselves, and do not make additions to the tracker dataset.
These charts are regularly updated based on the latest version of the response tracker.
OxCGRT is an ongoing collation project of live data. If you see any inaccuracies in the underlying data, or for specific feedback on the analysis or another aspect of the project please contact OxCGRT team. See the tracker’s notes and guidance on data quality.
The Imperial College London YouGov Covid-19 Behaviour Tracker Data Hub gathers global insights on people’s behaviors in response to COVID-19. This survey covers public behaviors and attitudes ranging from mask-wearing to self-isolation, social distancing, symptoms and testing.
The following chart shows monthly data on public willingness to receive the COVID-19 vaccine.
Data represents the share of respondents that agree with the following statement: “If a COVID-19 vaccine were made available to me this week, I would definitely get it.” Respondents were presented with a 1 to 5 scale, ranging from “Strongly agree” (1) to “Strongly disagree” (5). We consider responses of 1 or 2 to be in agreement with the statement.
The speed at which the first COVID-19 vaccines were developed was extraordinary. We have previously looked into the history of vaccine development. The measles vaccine was found relatively rapidly: it took only 10 years from the discovery of the pathogen to the development of the first vaccine. But for typhoid it took more than a century, and for some diseases for which we’ve known the pathogens for more than a century (like malaria) we still haven’t found an effective vaccine.
The development of a vaccine against COVID-19 has been much faster than the development of any other vaccine. Within less than a year several successful vaccines have already been announced and were approved for use in some countries.
The hope is that even more manufacturers develop vaccines for COVID-19. This will be important because eventually a very large share of the world population needs to receive a COVID-19 vaccine.
Several institutions maintain websites on which they list COVID-19 candidate vaccines that are currently being developed:
- The London School of Hygiene & Tropical Medicine Vaccine Tracker is updated weekly and shows the current stage of each development.
- WHO Vaccine Tracker – The WHO is tracking the COVID-19 candidate vaccines that are under development.
- Milken Institute Vaccine Tracker – The Milken Institute publishes, and regularly updates a tracker of possible treatments and vaccines for COVID-19 that scientists are currently working on.
- New York Times – The NYT tracker includes brief summaries of each development.
You can download the full dataset alongside the detailed source descriptions on GitHub.
Note that other countries may have also started vaccination campaigns—we’ll add them to our maps and charts as soon as numbers are verifiable based on public official sources.
We do not include participants in the vaccine arm of clinical trials, as this data is not available for many of the hundreds of trials currently taking place.
The population estimates we use to calculate per-capita metrics are all based on the last revision of the United Nations World Population Prospects. The exact values can be viewed in our GitHub repository.
Location | Source | Last observation date | Vaccines |
---|---|---|---|
Albania | Ministry of Health | February 25, 2021 | Pfizer/BioNTech |
Algeria | Ministry of Health | February 19, 2021 | Sputnik V |
Andorra | Government of Andorra | February 24, 2021 | Pfizer/BioNTech |
Anguilla | Ministry of Health | February 14, 2021 | Oxford/AstraZeneca |
Argentina | Ministry of Health | February 26, 2021 | Sputnik V |
Australia | Government of Australia via covidlive.com.au | February 26, 2021 | Pfizer/BioNTech |
Austria | Ministry of Health | February 26, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Azerbaijan | Government of Azerbaijan | February 6, 2021 | Oxford/AstraZeneca, Sputnik V |
Bahrain | Ministry of Health | February 26, 2021 | Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V |
Bangladesh | Directorate General of Health Services | February 25, 2021 | Oxford/AstraZeneca |
Barbados | Ministry of Health | February 25, 2021 | Oxford/AstraZeneca |
Belarus | Ministry of Health | February 18, 2021 | Sputnik V |
Belgium | Sciensano | February 25, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Bermuda | Government of Bermuda | February 22, 2021 | Pfizer/BioNTech |
Bolivia | Ministry of Health | February 11, 2021 | Sputnik V |
Brazil | Regional governments via Coronavirus Brasil | February 26, 2021 | Oxford/AstraZeneca, Sinovac |
Bulgaria | Ministry of Health | February 26, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Cambodia | Ministry of Health | February 25, 2021 | Sinopharm/Beijing |
Canada | Government of Canada | February 26, 2021 | Moderna, Pfizer/BioNTech |
Cayman Islands | Cayman Islands Government | February 25, 2021 | Pfizer/BioNTech |
Chile | Department of Statistics and Health Information | February 26, 2021 | Pfizer/BioNTech, Sinovac |
China | National Health Commission | February 9, 2021 | Sinopharm/Beijing, Sinopharm/Wuhan, Sinovac |
Colombia | Ministry of Health | February 26, 2021 | Pfizer/BioNTech |
Costa Rica | National Health Commission | February 22, 2021 | Pfizer/BioNTech |
Croatia | Ministry of Health | February 25, 2021 | Pfizer/BioNTech |
Cyprus | Government of Cyprus | February 20, 2021 | Pfizer/BioNTech |
Czechia | Ministry of Health | February 26, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Denmark | Statens Serum Institut | February 25, 2021 | Moderna, Pfizer/BioNTech |
Dominican Republic | Ministry of Public Health | February 24, 2021 | Oxford/AstraZeneca |
Ecuador | Government of Ecuador via Ecuacovid | February 24, 2021 | Pfizer/BioNTech |
Egypt | Ministry of Health | January 30, 2021 | Sinopharm/Beijing |
El Salvador | Ministry of Health | February 22, 2021 | Oxford/AstraZeneca |
England | Government of the United Kingdom | February 25, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech |
Estonia | National Health Board | February 25, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Faeroe Islands | Government of the Faeroe Islands | February 24, 2021 | Pfizer/BioNTech |
Falkland Islands | Government of the Falkland Islands | February 15, 2021 | Oxford/AstraZeneca |
Finland | Finnish Institute for Health and Welfare | February 26, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
France | Public Health France | February 25, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Germany | Robert Koch Institut | February 26, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Gibraltar | Government of Gibraltar | February 25, 2021 | Pfizer/BioNTech |
Greece | Ministry of Health | February 26, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Greenland | Government of Greenland | January 27, 2021 | Pfizer/BioNTech |
Guernsey | Government of Guernsey | February 23, 2021 | Pfizer/BioNTech |
Guyana | Ministry of Health | February 22, 2021 | Oxford/AstraZeneca |
Hungary | Government of Hungary | February 26, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V |
Iceland | Directorate of Health | February 26, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
India | Ministry of Health | February 26, 2021 | Covaxin, Oxford/AstraZeneca |
Indonesia | Ministry of Health | February 26, 2021 | Sinovac |
Iran | Government of Iran | February 17, 2021 | Sputnik V |
Ireland | Heath Service Executive | February 23, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Isle of Man | Isle of Man Government | February 26, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech |
Israel | Government of Israel | February 26, 2021 | Moderna, Pfizer/BioNTech |
Italy | Extraordinary commissioner for the Covid-19 emergency | February 26, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Japan | Ministry of Health, Labour and Welfare | February 26, 2021 | Pfizer/BioNTech |
Jersey | Government of Jersey | February 21, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech |
Kazakhstan | Government of Kazakhstan | February 24, 2021 | Sputnik V |
Kuwait | Ministry of Health | February 15, 2021 | Pfizer/BioNTech |
Latvia | National Health Service | February 26, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Lebanon | Government of Lebanon | February 26, 2021 | Pfizer/BioNTech |
Liechtenstein | Federal Office of Public Health | February 24, 2021 | Moderna, Pfizer/BioNTech |
Lithuania | Ministry of Health | February 26, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Luxembourg | Government of Luxembourg | February 25, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Macao | Government of Macao | February 18, 2021 | Sinopharm/Beijing |
Maldives | Presidency of the Maldives | February 26, 2021 | Oxford/AstraZeneca |
Malta | COVID-19 Malta Public Health Response Team | February 25, 2021 | Pfizer/BioNTech |
Mauritius | National Communication Committee on COVID-19 | February 17, 2021 | Oxford/AstraZeneca |
Mexico | Secretary of Health | February 26, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V |
Monaco | National Council | January 18, 2021 | Pfizer/BioNTech |
Montenegro | Government of Montenegro | February 26, 2021 | Sputnik V |
Morocco | Ministry of Health | February 26, 2021 | Oxford/AstraZeneca, Sinopharm/Beijing |
Myanmar | Ministry of Health | February 2, 2021 | Oxford/AstraZeneca |
Nepal | Government of Nepal | February 20, 2021 | Oxford/AstraZeneca |
Netherlands | National Institute for Public Health and the Environment | February 25, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
New Zealand | Ministry of Health | February 24, 2021 | Pfizer/BioNTech |
Northern Cyprus | Ministry of Health | January 22, 2021 | Pfizer/BioNTech, Sinovac |
Northern Ireland | Government of the United Kingdom | February 25, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech |
Norway | Norwegian Institute of Public Health | February 25, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Oman | Ministry of Health | February 23, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech |
Pakistan | National Command and Operation Centre | February 21, 2021 | Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V |
Panama | Ministry of Health | February 25, 2021 | Pfizer/BioNTech |
Paraguay | Government of Paraguay | February 25, 2021 | Sputnik V |
Peru | Ministry of Health | February 25, 2021 | Sinopharm/Beijing |
Poland | Ministry of Health | February 26, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Portugal | General Directorate of Health via Data Science for Social Good | February 26, 2021 | Moderna, Pfizer/BioNTech |
Qatar | National Strategic Group on COVID-19 | February 18, 2021 | Pfizer/BioNTech |
Romania | Government of Romania | February 26, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Russia | Russian Direct Investment Fund | February 10, 2021 | Sputnik V |
Saint Helena | Government of Saint Helena | February 3, 2021 | Oxford/AstraZeneca |
Saudi Arabia | Saudi Health Council | February 26, 2021 | Pfizer/BioNTech |
Scotland | Government of the United Kingdom | February 25, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech |
Senegal | Ministry of Health | February 25, 2021 | Sinopharm/Beijing |
Serbia | Government of Serbia | February 26, 2021 | Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V |
Seychelles | Extended Programme for Immunisation | February 25, 2021 | Oxford/AstraZeneca, Sinopharm/Beijing |
Singapore | Ministry of Health | February 18, 2021 | Pfizer/BioNTech |
Slovakia | Ministry of Health | February 26, 2021 | Pfizer/BioNTech |
Slovenia | National Institute of Public Health, via Sledilnik | February 26, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech |
South Africa | Ministry of Health | February 26, 2021 | Johnson&Johnson |
South Korea | Korea Centers for Disease Control and Prevention | February 26, 2021 | Oxford/AstraZeneca |
Spain | Ministry of Health | February 25, 2021 | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Sri Lanka | Ministry of Health | February 25, 2021 | Oxford/AstraZeneca |
Sweden | Public Health Agency of Sweden | February 26, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech |
Switzerland | Federal Office of Public Health | February 24, 2021 | Moderna, Pfizer/BioNTech |
Trinidad and Tobago | Ministry of Health | February 22, 2021 | Oxford/AstraZeneca |
Turkey | COVID-19 Vaccine Information Platform | February 26, 2021 | Sinovac |
Turks and Caicos Islands | Ministry of Health | February 8, 2021 | Pfizer/BioNTech |
Ukraine | Ministry of Health | February 26, 2021 | Oxford/AstraZeneca |
United Arab Emirates | National Emergency Crisis and Disaster Management Authority | February 26, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinopharm/Wuhan, Sputnik V |
United Kingdom | Government of the United Kingdom | February 25, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech |
United States | Centers for Disease Control and Prevention | February 26, 2021 | Moderna, Pfizer/BioNTech |
Venezuela | Government of Venezuela | February 22, 2021 | Sputnik V |
Wales | Government of the United Kingdom | February 25, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech |
Zimbabwe | Ministry of Health | February 26, 2021 | Sinopharm/Beijing |
Sign up for regular updates from Our World in Data
→ If you want to keep up-to-date with on our work on COVID-19, and the many other topics we cover you can sign up to our newsletter.